KAZIA THERAPEUTICS-SPON ADR (KZIA) Stock Price, Quote, News and Overview
NASDAQ:KZIA - Nasdaq - US48669G2049 - ADR - Currency: USD
KZIA Quote, Performance and Key Statistics
1.18
+0.33 (+39.63%)
The current stock price of KZIA is 1.18 USD. In the past month the price decreased by -21.33%. In the past year, price decreased by -43.16%.
KZIA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.17 | 378.30B | ||
| AMGN | AMGEN INC | 16.39 | 174.51B | ||
| GILD | GILEAD SCIENCES INC | 25.47 | 146.22B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1683.76 | 125.39B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.5 | 77.34B | ||
| ARGX | ARGENX SE - ADR | 231.21 | 36.10B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.66B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.47B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.08B | ||
| BIIB | BIOGEN INC | 9.13 | 22.01B | ||
| NTRA | NATERA INC | N/A | 19.02B | ||
| GMAB | GENMAB A/S -SP ADR | 24.89 | 15.34B |
Related stock screener links
About KZIA
Company Profile
Kazia Therapeutics Ltd is a AU-based company operating in Biotechnology industry. The company is headquartered in Sydney, New South Wales. Kazia Therapeutics Limited is an oncology focused drug development company. The firm is engaged in the pharmaceutical research and development. Its lead program includes Paxalisib and EVT801. Paxalisib is a small molecule inhibitor of the PI3K / Akt / mTOR pathway, a central regulator of growth and cell division that is dysregulated in many types of cancer. Paxalisib is being developed for several forms of brain cancer. EVT801 is a small molecule inhibitor of vascular endothelial growth factor receptor 3 (VEGFR3), which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. EVT801 is an inhibitor of VEGFR3, a cellular receptor for VEGF. The Company’s drug candidates are designed to treat disease, such as brain cancer, renal cancer, and liver cancer.
Company Info
KAZIA THERAPEUTICS-SPON ADR
Three International Towers Level 24,, 300 Barangaroo Avenue
Sydney NEW SOUTH WALES 2000 AU
CEO: James Garner
Employees: 0
Company Website: https://www.kaziatherapeutics.com/
Investor Relations: http://www.novogen.com/investorcentre
Phone: 1161298780088
KAZIA THERAPEUTICS-SPON ADR / KZIA FAQ
What is the stock price of KAZIA THERAPEUTICS-SPON ADR today?
The current stock price of KZIA is 1.18 USD. The price increased by 39.63% in the last trading session.
What is the ticker symbol for KAZIA THERAPEUTICS-SPON ADR stock?
The exchange symbol of KAZIA THERAPEUTICS-SPON ADR is KZIA and it is listed on the Nasdaq exchange.
On which exchange is KZIA stock listed?
KZIA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for KAZIA THERAPEUTICS-SPON ADR stock?
7 analysts have analysed KZIA and the average price target is 11.27 USD. This implies a price increase of 855.17% is expected in the next year compared to the current price of 1.18. Check the KAZIA THERAPEUTICS-SPON ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is KAZIA THERAPEUTICS-SPON ADR worth?
KAZIA THERAPEUTICS-SPON ADR (KZIA) has a market capitalization of 6.60M USD. This makes KZIA a Nano Cap stock.
How many employees does KAZIA THERAPEUTICS-SPON ADR have?
KAZIA THERAPEUTICS-SPON ADR (KZIA) currently has 0 employees.
What are the support and resistance levels for KAZIA THERAPEUTICS-SPON ADR (KZIA) stock?
KAZIA THERAPEUTICS-SPON ADR (KZIA) has a resistance level at 1.68. Check the full technical report for a detailed analysis of KZIA support and resistance levels.
Is KAZIA THERAPEUTICS-SPON ADR (KZIA) expected to grow?
The Revenue of KAZIA THERAPEUTICS-SPON ADR (KZIA) is expected to decline by -100% in the next year. Check the estimates tab for more information on the KZIA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy KAZIA THERAPEUTICS-SPON ADR (KZIA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of KZIA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of KZIA, evaluating the profitability, health, valuation and growth aspects
- KAZIA THERAPEUTICS-SPON ADR (KZIA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- KAZIA THERAPEUTICS-SPON ADR (KZIA) Sales and EPS estimates to see what analysts future expectations are.
- KAZIA THERAPEUTICS-SPON ADR (KZIA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- KAZIA THERAPEUTICS-SPON ADR (KZIA) Insider and Institutional Ownership to learn about the owners and their transactions.
- KAZIA THERAPEUTICS-SPON ADR (KZIA) Stock Chart to make your own analysis
- KAZIA THERAPEUTICS-SPON ADR (KZIA) Latest news and press-releases to stay up to date.
Does KAZIA THERAPEUTICS-SPON ADR (KZIA) stock pay dividends?
KZIA does not pay a dividend.
What is the Price/Earnings (PE) ratio of KAZIA THERAPEUTICS-SPON ADR (KZIA)?
KAZIA THERAPEUTICS-SPON ADR (KZIA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.21).
What is the Short Interest ratio of KAZIA THERAPEUTICS-SPON ADR (KZIA) stock?
The outstanding short interest for KAZIA THERAPEUTICS-SPON ADR (KZIA) is 8.1% of its float. Check the ownership tab for more information on the KZIA short interest.
KZIA Technical Analysis
KZIA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to KZIA. KZIA may be in some trouble as it scores bad on both profitability and health.
KZIA Financial Highlights
Over the last trailing twelve months KZIA reported a non-GAAP Earnings per Share(EPS) of -3.21. The EPS increased by 92.01% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -124.06% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
KZIA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to KZIA. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of -47372.73% and a revenue growth -100% for KZIA